Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05650528
Registration number
NCT05650528
Ethics application status
Date submitted
29/11/2022
Date registered
14/12/2022
Date last updated
1/08/2023
Titles & IDs
Public title
QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects
Query!
Scientific title
Single-center, Randomised, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile of Single- and Multiple-dose Ascending Oral QG101-23-0 Capsules in Healthy Subjects
Query!
Secondary ID [1]
0
0
Aom0315-ACT-01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - QG101-23-0 capsules
Treatment: Drugs - Placebo
Experimental: Part A - Five ascending dose levels (Cohort A1?Cohort A2?Cohort A3?Cohort A4 and Cohort A5) of SAD QG101-23-0 capsules (n=6) or placebo (n=2)
Experimental: Part B - Three ascending dose levels (Cohort B1?Cohort B2?Cohort B3) of MAD QG101-23-0 capsules (n=6) or placebo (n=2)
Experimental: Part C - Cohort A3 Group 1 (n=8) and Group 2 (n=6) will participate in the food effect study. The subjects will take QG101-23-0 capsules while under fasting or fed condition.
Treatment: Drugs: QG101-23-0 capsules
Single and Multiple Dose for oral
Treatment: Drugs: Placebo
Single and Multiple Dose for oral
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The safety and tolerability of single-dose ascending of oral QG101-23-0 capsules in healthy subjects
Query!
Assessment method [1]
0
0
Safety will be assessed by the number, severity and type of adverse events, including changes in clinical laboratory evaluations (e.g., Hematology, urinalysis, blood biochemistry, coagulation), vital signs (blood pressure, pulse rate, tympanic thermometers temperature and respiratory rate), ECGs (e.g., QTc interval, QRS duration, PR interval) and physical examinations
Query!
Timepoint [1]
0
0
Day1-8 (SAD)
Query!
Primary outcome [2]
0
0
The safety and tolerability of multiple-dose ascending oral QG101-23-0 capsules in healthy subjects
Query!
Assessment method [2]
0
0
Safety will be assessed by the number, severity and type of adverse events, including changes in clinical laboratory evaluations (e.g., Hematology, urinalysis, blood biochemistry, coagulation), vital signs (blood pressure, pulse rate, tympanic thermometers temperature and respiratory rate), ECGs (e.g., QTc interval, QRS duration, PR interval) and physical examinations
Query!
Timepoint [2]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [1]
0
0
Maximum observed concentration(Cmax)
Query!
Assessment method [1]
0
0
Pharmacokinetics
Query!
Timepoint [1]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [2]
0
0
Time of Cmax(Tmax)
Query!
Assessment method [2]
0
0
Pharmacokinetics
Query!
Timepoint [2]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [3]
0
0
Area under the concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration(AUC0-t)
Query!
Assessment method [3]
0
0
Pharmacokinetics
Query!
Timepoint [3]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [4]
0
0
AUC from time 0 to 12 hours(AUC0-12)
Query!
Assessment method [4]
0
0
Pharmacokinetics
Query!
Timepoint [4]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [5]
0
0
AUC from time 0 to 24 hours(AUC0-24)
Query!
Assessment method [5]
0
0
Pharmacokinetics
Query!
Timepoint [5]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [6]
0
0
AUC extrapolated from time 0 to infinity(AUC0-8)
Query!
Assessment method [6]
0
0
Pharmacokinetics
Query!
Timepoint [6]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [7]
0
0
Apparent terminal elimination half-life (t1/2)
Query!
Assessment method [7]
0
0
Pharmacokinetics
Query!
Timepoint [7]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [8]
0
0
Apparent distribution volume corrected for bioavailability(Vd/F)
Query!
Assessment method [8]
0
0
Pharmacokinetics
Query!
Timepoint [8]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [9]
0
0
Apparent volume of distribution at steady-state (Vss)
Query!
Assessment method [9]
0
0
Pharmacokinetics
Query!
Timepoint [9]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [10]
0
0
Apparent terminal elimination rate constant (?z)
Query!
Assessment method [10]
0
0
Pharmacokinetics
Query!
Timepoint [10]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [11]
0
0
Mean residence time (MRT)
Query!
Assessment method [11]
0
0
Pharmacokinetics
Query!
Timepoint [11]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [12]
0
0
Apparent total clearance (CL)
Query!
Assessment method [12]
0
0
Pharmacokinetics
Query!
Timepoint [12]
0
0
Day1-8 (SAD)
Query!
Secondary outcome [13]
0
0
Observed maximum concentration at steady state (Cmax,ss)
Query!
Assessment method [13]
0
0
Pharmacokinetics
Query!
Timepoint [13]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [14]
0
0
Observed minimum concentration at steady state (Cmin,ss)
Query!
Assessment method [14]
0
0
Pharmacokinetics
Query!
Timepoint [14]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [15]
0
0
Time of Cmax at steady state (Tmax,ss)
Query!
Assessment method [15]
0
0
Pharmacokinetics
Query!
Timepoint [15]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [16]
0
0
Average Concentration at steady state (Cav,ss)
Query!
Assessment method [16]
0
0
Pharmacokinetics
Query!
Timepoint [16]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [17]
0
0
Time of observed minimum concentration at steady state (Tmin,ss)
Query!
Assessment method [17]
0
0
Pharmacokinetics
Query!
Timepoint [17]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [18]
0
0
After steady state, the interval from 0 point of one administration to administration t Area under the plasma concentration - time curve (AUC0-t,ss)
Query!
Assessment method [18]
0
0
Pharmacokinetics
Query!
Timepoint [18]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [19]
0
0
After steady state, the area under the blood concentration - time curve from 0 point of one administration to infinity (AUC0-8,ss)
Query!
Assessment method [19]
0
0
Pharmacokinetics
Query!
Timepoint [19]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [20]
0
0
Area under the concentration-time curve from time 0 to the end of the dosing interval (AUC0-tau)
Query!
Assessment method [20]
0
0
Pharmacokinetics
Query!
Timepoint [20]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [21]
0
0
Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)
Query!
Assessment method [21]
0
0
Pharmacokinetics
Query!
Timepoint [21]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [22]
0
0
Apparent terminal elimination half-life (t1/2)
Query!
Assessment method [22]
0
0
Pharmacokinetics
Query!
Timepoint [22]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [23]
0
0
CL for bioavailability at steady state (CL/F, ss)
Query!
Assessment method [23]
0
0
Pharmacokinetics
Query!
Timepoint [23]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [24]
0
0
Vd/F at steady state (Vd/F, ss)
Query!
Assessment method [24]
0
0
Pharmacokinetics
Query!
Timepoint [24]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [25]
0
0
Mean residence time (MRT)
Query!
Assessment method [25]
0
0
Pharmacokinetics
Query!
Timepoint [25]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [26]
0
0
Accumulation ratio (AR)
Query!
Assessment method [26]
0
0
Pharmacokinetics
Query!
Timepoint [26]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [27]
0
0
Accumulation ratios for Cmax
Query!
Assessment method [27]
0
0
Pharmacokinetics
Query!
Timepoint [27]
0
0
Day1-15 (MAD)
Query!
Secondary outcome [28]
0
0
Accumulation ratios for AUC
Query!
Assessment method [28]
0
0
Pharmacokinetics
Query!
Timepoint [28]
0
0
Day1-15 (MAD)
Query!
Eligibility
Key inclusion criteria
Subjects must satisfy all the following criteria at the Screening visit and Check-in unless
otherwise stated:
1. Males or females, between 18 and 55 years of age, inclusive.
2. Body weight is = 50.0 kg for male subjects and = 45.0 kg for female subjects, with a
body mass index (BMI) of 18-32 kg / m2 (inclusive).
3. In good health, determined by no clinically significant findings from medical history,
physical examination, 12-lead electrocardiogram (ECG), vital signs measurements, and
clinical laboratory evaluations at Screening and Check-in as assessed by the
Investigator (or designee), as applicable. Resting heart rate = 45 bpm and = 100 bpm
at Screening.
4. Male subjects must agree to refrain from sperm donation from the time of signing the
informed consent form until 90 days after the last dosing and females should refrain
from ova donation from the time of signing the informed consent form until 30 days
after the last dosing. As detailed in Appendix 2.
5. Females will not be pregnant or lactating, female subjects with a negative blood
pregnancy test during the Screening period and a negative urine pregnancy test at
Check-in, and male and female of childbearing potential having taken effective
contraceptive measures at least from the date of signing the informed consent form and
should agree to continue to use effective contraceptive measures from the date of
signing the informed consent form until 90 days after the last dosing for males and 30
days after the last dosing for females. Males with vasectomy at least 90 days prior to
the Screening visit must have documentation confirming Azoospermia or use other
contraceptives. As detailed in Appendix 2.
6. Females of nonchildbearing potential defined as permanently sterile (i.e., due to
hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy; at least 3
months between sterlization date and screening date) or postmenopausal (defined as at
least 12 months post cessation of menses without an alternative medical cause and
follicle-stimulating hormone [FSH] level = 30 IU/L). As detailed in Appendix 2.
7. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by
the study restrictions.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Subjects will be excluded from the study if they satisfy any of the following criteria at
the Screening visit and Check-in unless otherwise stated:
1. Significant history or clinical manifestation of any metabolic, dermatological,
hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal,
neurological, respiratory, endocrine, or psychiatric disorder, acute or chronic
infectious diseases and malignancies, as determined by the Investigator (or designee).
2. History of hereditary bleeding disorders, coagulation disorders, non-traumatic
bleeding requiring treatment, or thromboembolism; or currently have any disease that
can cause bleeding (including coagulation disorder, thrombocytopenia [platelet count <
150×109/L] and prothrombin time-international normalised ratio > 1.5);
3. Acute and chronic liver disease or serum aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) = 1.5 × the upper limit of normal at Screening or Check-in;
4. History of acute and chronic kidney disease including acute and chronic renal
insufficiency. Or impaired renal function defined by creatinine clearance (calculated
using the Cockcroft-Gault equation) < 90 mL/min at Screening or Check-in; See Appendix
3 Formulas Used in the Study.
5. Abnormal blood pressure (defined as systolic blood pressure > 145 mmHg or < 90 mmHg,
diastolic blood pressure > 90 mmHg or < 50 mmHg) at Screening or Check-in;
6. History of clinically significant hypersensitivity, any intolerance, or any
anaphylaxis to any drug compound including any components of the study drug capsules,
such as lactose, hydroxypropyl methylcellulose, magnesium stearate, food, or other
substance, unless approved by the Investigator (or designee).
7. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab),
and/or positive human immunodeficiency virus (HIV) test at Screening. Participants
with previously treated HCV and hence HCV Ab positive may be included if a subsequent
HCV RNA test is negative.
8. Any of the following on the ECG at Screening and Check-in (Day -1).
1. ECG is abnormal and clinically significant, or the corrected QTc interval (QTc is
calculated by Fridericia correction formula: QTc = QT/ [RR ^ 0.33]) > 450 msec
(male) or > 470 msec (female) is confirmed by repeat measurement at least two
times. See Appendix 3 Formulas Used in the Study.
2. QRS duration > 120 msec, confirmed by repeat measurement at least two times.
3. PR interval > 220 msec, confirmed by repeat measurement at least two times.
4. Findings which would make QTc measurements difficult or QTc data uninterpretable.
5. History of additional risk factors for torsades de pointes (e.g., heart failure,
hypokalaemia, family history of long QT syndrome).
6. Abnormal QRS or ST segment indicates a clinically significant abnormality of
myocardia, e.g., cardiomyopathy, cardiac ischaemia or myocardial infarction, etc.
9. History of stomach or intestinal surgery or resection, vagotomy, or any surgery
(uncomplicated appendectomy and hernia repair will be allowed, but not
cholecystectomy) or adverse syndromes (such as Crohn's disease, Irritable Bowel
Syndrome , chronic pancreatitis or congenital nonhaemolytic hyperbilirubinemia [e.g.,
suspicion of Gilbert's syndrome based on total and direct bilirubin, the subjects with
total or direct or indirect bilirubin > 35%× the upper limit of normal at Screening or
Check-in]) that would potentially alter gastrointestinal peristalsis, pH, absorption
and/or excretion of orally administered drugs.
10. Pregnant or lactating females or females of childbearing potential and males are
unwilling to take effective contraceptive measures.
11. Having foods and beverages containing poppy seeds, grapefruit and orange including
Seville oranges or wine containing extracts from the above fruits within 3 days prior
to Check-in until the follow-up visit.
12. Use or intend to use any medications / products including any prescription or
over-the-counter drugs known to alter drug absorption, metabolism, or elimination
processes, including vitamin therapy, minerals, and phytotherapeutic / traditional
Chinese medicine such as St. John's wort /plant-derived preparations, within 30 days
prior to the first dose of study medication until completion of the follow-up visit,
unless deemed acceptable by the Investigator (or designee).
13. Having lost blood or donated blood 500 mL or more, within 56 days prior to Screening.
Receipt of blood products within 60 days prior to Check-in. The Participants who plan
to donate blood from the Screening to 56 days after the follow-up visit.
14. Participation in a clinical study involving administration of an investigational drug
or having received any vaccines (including any new investigational vaccines and any
approved vaccines such as influenza or COVID-19 vaccines) or a biological product
within 30 days (or within five half-lives of the test drug) prior to dosing.
15. History of drug/chemical abuse or substance abuse; Regular consumption of the amount
of alcohol (in an Australian standard drink) of more than two standard drinks per day
or 14 standard drinks per week within 6 months prior to your admission to the clinical
unit (One standard drink is equivalent to 10 grams of alcohol: approximately 285 mL
full-strength beer or cider [4.9%], 375 mL mid-strength beer [3.5%], 425 mL light-
strength beer [2.7%], 100 mL wine or 30 mL shot of 40% spirit). A positive alcohol
breath test at Screening or Day -1, or inability to abstain from alcohol during the
study (Within 3 days prior to Check-in until the follow-up visit); Urine drugs of
abuse testing as detailed in Appendix 4.
16. Positive alcohol breath test result or positive urine drug screen at Screening or
Check-in. Urine drugs of abuse testing as detailed in Appendix 4.
17. History of febrile illness within 7 days prior to the first dose of study drug or
subjects with evidence of active infection at Check-in.
18. Smoke more than five cigarettes per day within 30 days prior to dosing (Day 1) or
inability to abstain from tobacco- or nicotine-containing products during the study
(Within 3 days prior to Check-in until the check-out) or positive at Screening or
Check-in for any other reason.
19. Poor peripheral venous access.
20. History of constipation or the inability to maintain regular bowel movements for the
subjects of Cohort A3 within 3 months before administration.
21. In addition to the above, subject who, in the opinion of the Investigator (or
designee), should not participate in this study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/02/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/06/2024
Query!
Actual
Query!
Sample size
Target
70
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
CMAX Clinical Research Pty Ltd - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amckaus PTY LTD.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Novotech (Australia) Pty Limited
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study will consist of three parts: a single-dose ascending (SAD) phase (Part A) enrolling
a total of five ~ six cohorts of healthy participants, a multiple-dose ascending (MAD) phase
(Part B) enrolling 3 cohorts of healthy participants, and a food effect study (Part C).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05650528
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Angela Rowland
Query!
Address
0
0
CMAX Clinical Research Pty Ltd
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Huaqin Shi
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+86-571-86504023
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05650528
Download to PDF